NEW YORK, Jan 26 (Reuters) - Amgen (AMGN.O: Quote, Profile, Research) and Genentech Inc. (DNA.N: Quote, Profile, Research) on Thursday said they have entered into license agreements that give each company access to multiple patents relating to the manufacture and use of antibodies and related technology.